Express Scripts Pushing Manufacturers To Lower List Prices By Offering Cheaper Brand Alternatives
Companies should introduce same drug under new NDC at lower list price to overcome difficulties of reducing list prices on existing brands, PBM says.
You may also be interested in...
Rebate expectations appear to have got in the way of fast uptake for some of the leading pharmacy benefit managers, according to comments by executives at the Senate Finance Committee hearing April 9.
Gilead’s authorized generics for Epclusa and Harvoni will be first alternatives to benefit from preferred coverage on the pharmacy benefit manager's National Preferred Flex Formulary.
Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.